PALO ALTO, Calif., May 27 /PRNewswire-FirstCall/ -- CV Therapeutics,
Inc. (Nasdaq: CVTX) announced today that two clinical abstracts have been
accepted for presentation at the American Diabetes Association (ADA) 68th
Scientific Sessions, which will be held in San Francisco, CA on June 6 -
10, 2008.

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company primarily focused on applying molecular
cardiology to the discovery, development and commercialization of novel,
small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine
extended-release tablets), indicated for the treatment of chronic angina in
patients who have not achieved an adequate response with other antianginal
drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic
stress agent in radionuclide myocardial perfusion imaging in patients
unable to undergo adequate exercise stress. CV Therapeutics also has other
clinical and preclinical drug development candidates and programs that have
not been determined to be safe or effective in humans for any uses.

Except for the historical information contained herein, the matters set
forth in this press release, including statements as to research and
development and commercialization of products, are forward-looking
statements within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including operating losses and fluctuations
in operating results; capital requirements; regulatory review and approval
of our products; special protocol assessment agreement; the conduct and
timing of clinical trials; commercialization of products; market acceptance
of products; product labeling; concentrated customer base; reliance on
strategic partnerships and collaborations; uncertainties in drug
development; uncertainties regarding intellectual property and other risks
detailed from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements.

(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... ... as finalists in the World Technology Awards. uBiome is one of just six ... across all categories. , In addition to uBiome, companies nominated as finalists in ...

(Date:12/5/2016)... WASHINGTON , Dec. 5, 2016 The ... (NIJ), today published "Can CT Scans Enhance or ... examines the potential of supporting or replacing forensic ... a CT scan. In response to ... NIJ is exploring using CT scans as a ...

(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...